A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes
Sponsor: ProSciento, Inc.
Listed as NCT04956263, this PHASE2 trial focuses on Diabetes and Diabetes Mellitus and remains completed. Sponsored by ProSciento, Inc., it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Feb 2023 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Mar 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE2
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ProSciento, Inc.
- Youngene Therapeutics Inc., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .